首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

全球 T 細胞療法市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1408996

全球 T 細胞療法市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global T-Cell Therapies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 T 細胞治療市場需求預計將從 2022 年的 24.8 億美元增至 2030 年的近 295.1 億美元，2023-2030 年研究期間CAGR為 36.28%。

T 細胞療法涉及使用 T 細胞（一種白血球）來治療各種疾病，特別是某些類型的癌症和免疫相關疾病。 T 細胞在免疫系統中至關重要，因為它們可以識別並消除異常或受感染的細胞。 T 細胞療法利用並增強人體的自然防禦機制來瞄準和破壞特定細胞。

市場動態

T 細胞療法市場是由這些療法的革命性潛力所推動的，特別是在癌症治療方面。癌症盛行率的增加以及對更精確、更有效的治療的需求推動了 T 細胞療法的採用，例如 CAR-T 細胞療法。生物技術和基因工程的進步發揮著至關重要的作用，使 T 細胞的基因修飾能夠增強對癌細胞的靶向作用。正面的臨床結果和已證實的療效有助於增強醫療保健專業人員和患者的信心，進一步促進市場的擴張。研究和開發方面的合作和投資加速了進展，從而開發出新的和改進的 T 細胞療法。監管批准和支援框架確保了可及性和商業化，從而加強了市場的成長軌跡。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球 T 細胞療法市場的各個細分市場進行了包容性評估。 T 細胞療法產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 T 細胞治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 T細胞療法市場的主要參與者包括諾華公司、默克公司、吉利德科學公司、TCR2 Therapeutics Inc.、Bluebird Bio Inc.、Sorrento Therapeutics、Fate Therapeutics、輝瑞公司、安進公司、新基公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：T 細胞療法公司的競爭格局

T細胞療法市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Novartis AG

公司簡介
公司收入
產品
最近的發展

Merck KGaA

公司簡介
公司收入
產品
最近的發展

Gilead Sciences Inc.

公司簡介
公司收入
產品
最近的發展

TCR2 Therapeutics Inc.

公司簡介
公司收入
產品
最近的發展

Bluebird Bio Inc.

公司簡介
公司收入
產品
最近的發展

Sorrento Therapeutics

公司簡介
公司收入
產品
最近的發展

Fate Therapeutics

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Amgen

公司簡介
公司收入
產品
最近的發展

Celgene Corporation

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113250

The global demand for T-Cell Therapies Market is presumed to reach the market size of nearly USD 29.51 BN by 2030 from USD 2.48 BN in 2022 with a CAGR of 36.28% under the study period 2023 - 2030.

T-cell therapies involve the use of T cells, a type of white blood cell, to treat various medical conditions, particularly certain types of cancers and immune-related disorders. T-cells are crucial in the immune system as these recognize and eliminate abnormal or infected cells. T-cell therapies harness and enhance the body's natural defense mechanisms to target and destroy specific cells.

MARKET DYNAMICS

The T-cell therapies market is driven by the revolutionary potential of these therapies, particularly in cancer treatment. The increasing cancer prevalence and the demand for more precise and effective treatments propel the adoption of T-cell therapies, such as CAR-T cell therapy. Advancements in biotechnology and genetic engineering play a crucial role, enabling the genetic modification of T cells for enhanced targeting of cancer cells. Positive clinical outcomes and demonstrated efficacy contribute to growing confidence among healthcare professionals and patients, further fostering the market's expansion. Collaborations and investments in research and development accelerate progress, leading to the development of new and improved T-cell therapies. Regulatory approvals and supportive frameworks ensure accessibility and commercialization, reinforcing the market's growth trajectory.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of t-cell therapies. The growth and trends of t-cell therapies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the t-cell therapies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

CART-Cell Therapy
T Cell Receptor (TCR)-Based
Tumor Infiltrating Lymphocytes (TIL)-Based

By Indication

Hematologic Malignancies (Lymphoma, Leukemia, Myeloma)
Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others)
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the T-Cell Therapies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the T-Cell Therapies market include Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . T-CELL THERAPIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY THERAPY TYPE

5.1 Overview by Therapy Type
5.2 Historical and Forecast Data
5.3 Analysis by Therapy Type
5.4 CAR T-cell Therapy Historic and Forecast Sales by Regions
5.5 T Cell Receptor (TCR)-based Historic and Forecast Sales by Regions
5.6 Tumor Infiltrating Lymphocytes (TIL)-based Historic and Forecast Sales by Regions

6 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Historic and Forecast Sales by Regions
6.5 Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE T-CELL THERAPIES COMPANIES

8.1. T-Cell Therapies Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF T-CELL THERAPIES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novartis AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Merck KGaA
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Gilead Sciences Inc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. TCR2 Therapeutics Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Bluebird Bio Inc.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Sorrento Therapeutics
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Fate Therapeutics
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Amgen
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Celgene Corporation
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers : Impact Analysis
Restraints : Impact Analysis
List of Raw Material
List of Raw Material Manufactures
List of Potential Buyers
Analysis by Therapy Type (USD MN)
CAR T-cell Therapy Market Sales by Geography (USD MN)
T Cell Receptor (TCR)-based Market Sales by Geography (USD MN)
Tumor Infiltrating Lymphocytes (TIL)-based Market Sales by Geography (USD MN)
Analysis Market by Indication (USD MN)
Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Market Sales by Geography (USD MN)
Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global T-Cell Therapies Market Sales by Geography (USD MN)
North America Market Analysis (USD MN)
United State Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate by Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of T-Cell Therapies Report
Market Research Process
Market Research Methodology
Global T-Cell Therapies Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Therapy Type
Market Attractiveness Analysis by Indication
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Market Analysis by Therapy Type (USD MN)
CAR T-cell Therapy Market Sales by Geography (USD MN)
T Cell Receptor (TCR)-based Market Sales by Geography (USD MN)
Tumor Infiltrating Lymphocytes (TIL)-based Market Sales by Geography (USD MN)
Global Market Analysis by Indication (USD MN)
Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Market Sales by Geography (USD MN)
Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Companies Market Share Analysis